Royal Bank Of Canada Jounce Therapeutics, Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.9 - $1.85 $3,144 - $6,463	-3,494 Reduced 59.71%	2,358 $4,000
Q4 2022 Feb 14, 2023	BUY	$0.64 - $1.99 $3,416 - $10,624	5,339 Added 1040.74%	5,852 $6,000
Q3 2022 Nov 14, 2022	BUY	$2.73 - $4.92 $753 - $1,357	276 Added 116.46%	513 $1,000
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $5,846 - $16,014	-2,088 Reduced 89.81%	237 $1,000
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $27,285 - $38,771	-4,540 Reduced 66.13%	2,325 $16,000
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $16,580 - $22,480	2,332 Added 51.44%	6,865 $58,000
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $9,954 - $17,241	1,975 Added 77.21%	4,533 $34,000
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $16,831 - $27,268	2,558 New	2,558 $17,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.